Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study concluded that hair follicle hyperplasia found in pseudolymphomatous folliculitis can also occur in genuine cutaneous lymphomas, potentially as a coincidental result of underlying pathological processes.

Benign Prostatic Hyperplasia may be caused by changes in how the body processes male hormones.

This study found that silver nanoparticles synthesized using Mitracarpus scaber extract showed potential hepatoprotective and anti-hyperplastic effects in rats, suggesting novel therapeutic strategies for managing liver injury and benign prostatic hyperplasia.

This study observed that men receiving dutasteride for benign prostatic hyperplasia did not show significant differences in neuropsychological assessments compared to a control group not on dutasteride.

This study found that 5-alpha-reductase inhibitor monotherapy for symptomatic benign prostatic hyperplasia showed some clinical benefit over placebo but was linked to a higher incidence of sexual side effects.

In this review, the authors aim to improve the differential diagnosis between hyperandrogenic PCOS and NCAH, which could lead to more personalized treatment strategies for patients experiencing hyperandrogenism.

This literature review identified that phosphodiesterase 5 inhibitors, such as Tadalafil, are highly effective in improving lower urinary tract symptoms associated with benign prostatic hyperplasia, while the efficacy of saw palmetto remains inconsistent.

In this study, the ethanol extract of Zapoteca portoricensis stem significantly reduced markers of testosterone-induced benign prostate hyperplasia in male albino rats without harming liver and kidney function.

This case report highlights the challenges in diagnosing simple-virilizing congenital adrenal hyperplasia, emphasizing the importance of early expert evaluation to prevent irreversible changes such as virilization.

This study found that ethanol extract of Syzygium aromaticum (clove) leaves significantly improved lipid profiles and increased body weight in testosterone-induced benign prostatic hyperplasia rats, suggesting potential anti-hyperlipidemic effects and modulation of body weight through metabolic activity.

High doses of finasteride cause cell growth and tumors in mice.

This article reviews the clinical complications and increased mortality risks associated with Cushing's syndrome but does not present new clinical data; it emphasizes the need for prompt treatment to mitigate these risks.

This review covers the pathophysiology, diagnosis, and treatment of congenital adrenal hyperplasia due to 21-hydroxylase deficiency and reports no new findings.

This study found that long-term dutasteride therapy in men with benign prostatic hyperplasia worsened erectile dysfunction, reduced testosterone levels, and increased blood glucose and lipid profile, indicating negative metabolic impacts.

This study found that long-term finasteride therapy in men with BPH worsened erectile dysfunction and reduced testosterone levels, while these effects were not observed with tamsulosin.

This study found that women with nonclassic congenital adrenal hyperplasia (NC-CAH) reported lower sexual function and higher sexual distress compared to those with classic CAH (C-CAH), particularly among those showing signs of androgen excess.

This study found that age is the most significant risk factor for hemorrhagic cystitis after hematopoietic stem-cell transplantation, with additional risk factors including cyclophosphamide-based prophylaxis and, among male recipients, prostatic hyperplasia.

The study observed that women with congenital adrenal hyperplasia experience more impaired sexual functions and are more often homosexually or bisexually oriented than those with polycystic ovary syndrome.

This study found that while new treatments like Optilume, Rezum, and Aquablation have minimal risks of sexual dysfunction, they offer less improvement in lower urinary tract symptoms compared to traditional surgeries like TURP, though Aquablation does reduce ejaculatory dysfunction more effectively than TURP.

This study found that Thermobalancing therapy using Dr Allen's Device significantly improved symptoms and quality of life in men with benign prostatic hyperplasia, but larger prostate sizes may require longer treatment.

This study found that US adults with classic congenital adrenal hyperplasia most preferred a hypothetical adjunctive therapy that prevents glucocorticoid-induced weight gain over other potential benefits.

This review discusses nonclassical 21-hydroxylase deficiency as the most common autosomal recessive disorder in humans and highlights the effectiveness of glucocorticoid treatment in reversing related symptoms.

This study developed a detailed classification system for functional androgenization in females that may enhance diagnosis and personalized treatment by identifying individual dysfunctions.

This study found that high-dose pterostilbene potentially reduced prostate hyperplasia and had strong antioxidant effects in male rats with benign prostatic hyperplasia, suggesting it might be more effective than vitamin C and resveratrol in similar contexts.

This review discusses phytotherapy options for managing benign prostatic hyperplasia, noting some herbal agents show promise in trials for mild-moderate symptoms but more evidence is needed for others.

This review discusses the diagnostic criteria and management strategies for Polycystic Ovary Syndrome (PCOS) and highlights the need for comprehensive clinical assessment, but does not report new clinical findings.

This review discusses recent advancements in understanding and managing congenital adrenal hyperplasia, including improvements in screening, diagnostics, and potential genetic and cell-based treatments, but reports no new clinical findings.

This study determined that nonclassical congenital adrenal hyperplasia has a 2.2% prevalence among hyperandrogenic women in Spain, with basal serum 17-hydroxyprogesterone showing excellent diagnostic performance.

This review examines the epidemiology, pathophysiology, diagnosis, and management strategies for non-classic congenital hyperplasia due to 21-hydroxylase deficiency, and provides evidence-based recommendations for its treatment and genetic counseling.

This review discusses the pathophysiology, diagnosis, and treatment of congenital adrenal hyperplasia, but reports no new research results.